BCAX vs DSGN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
BCAX · Bicara Therapeutics$8.44 ▼ 7.46%
DSGN · Design Therapeutics$9.02 ▼ 3.22%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- BCAX -55.3%
- DSGN +4.4%
Head to head
| Metric | BCAX | DSGN |
|---|---|---|
| Price | $8.44 | $9.02 |
| Change today | ▼ 7.46% | ▼ 3.22% |
| Market cap | $560.31M | $577.61M |
| Return, 3 months | -64.2% | -40.8% |
| Return, year to date | -49.9% | -3.8% |
| Return, 1 year | -53.2% | +8.0% |
| P/E (TTM) | – | – |
| P/B | 1.4 | 2.9 |
| P/E percentile vs own 5y | 98th | 35th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -96.1% | -19.4% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -54.2% | -36.9% |
| Analyst target vs. price | +274.8% | +140.2% |
| Analyst buy share | 88% | 100% |
| RSI (14) | 28 | 33 |
| 30-day volatility | 189.3% | 68.5% |
| Max drawdown, 1 year | -73.9% | -43.4% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- DSGN is the largest of the group by market value.
- DSGN has returned the most over the past year.
- DSGN has been the calmest stock over the last 30 days.